Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Myelodysplastic Syndrome
Interventions: Azacitidine for Injection, Vidaza®; Drug
Lead sponsor: Bioniche Pharma USA LLC; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Anaheim, California • Corona, California • Fresno, California + 1 more

Conditions: Pregnant Patients at Risk of Gestational Diabetes
Interventions: Prepared meals, Unprepared Pantry/Produce box; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Healthy Volunteers
Interventions: TAK-788, Itraconazole, Rifampin; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Obesity, Type 2 Diabetes
Interventions: No intervention planned.; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 99 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Non Insulin Dependent Diabetes, Pregnancy
Interventions: Metformin, Insulin; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Liver Diseases
Interventions: Novel MRI Software, Ensure Plus Nutrition Shake; Device · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 7 Years and older
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hyperglycaemia (Diabetic)
Interventions: Dichloroacetate, Placebo oral capsule; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Energy Deficiency Due to Short-term Fasting
Interventions: r-metHuLeptin; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 30 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Participants
Interventions: Zibotentan/Dapagliflozin FDC; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Glendale, California

Conditions: Bipolar Disorder
Interventions: Lithium; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 25 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Diabetes, Metabolic Diseases
Interventions: water-only 24-hour fasting once per week for 6 weeks; Behavioral
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 30 Years to 69 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 2
States / cities: Murray, Utah • Salt Lake City, Utah

Conditions: C-Met Exon 14 Mutation
Interventions: Glumetinib; Drug
Lead sponsor: Haihe Biopharma Co., Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Louisville, Kentucky

Conditions: Healthy
Interventions: 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets, 5 mg/500 mg METAGLIP™ Tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 2
States / cities: East Grand Forks, Minnesota • Fargo, North Dakota

Conditions: Dietary Exposure
Interventions: Vitamin C gummy, Vitamin C tablet; Dietary Supplement
Lead sponsor: Church & Dwight Company, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Healthy
Interventions: Albuterol Sulfate Extended-Release Tablets 8 mg, VoSpire® ER Tablets 8 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Prolonged QTc Interval, Pharmacokinetic
Interventions: 100 μg cebranopadol, 200 μg cebranopadol, 400 μg cebranopadol, Placebo to cebranopadol encapsulated tablets, 400 mg Moxifloxacin, Placebo to moxifloxacin encapsulated tablets; Drug
Lead sponsor: Tris Pharma, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 171 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Interventions: Insulin aspart, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years to 89 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Healthy Volunteers
Interventions: ASP1617, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Glendale, California

Conditions: Type 2 Diabetes Mellitus
Interventions: Lixisenatide (AVE0010), Placebo, Insulin glargine, Pen auto-injector, Metformin, Thiazolidinedione (TZD); Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 23
States / cities: Mesa, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 19 more

Conditions: Prediabetes
Interventions: Hourly 3-Minute Light Walking Breaks, Hourly Stair-Climbing Exercise Snacks; Behavioral
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 69 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy, Volunteer
Interventions: Mirdametinib, Mirdametinib and Carbamazepine; Drug
Lead sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions: TBAJ-876, Midazolam, Digoxin; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Health Behavior
Interventions: peer counseling, Feedback report; Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy, Food-drug Interaction
Interventions: Relacorilant Fasted, Relacorilant with a high fat breakfast, Relacorilant with a moderate breakfast; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Search by objective public record fields.

Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients

A Randomized Controlled Trial of Prepared vs. Unprepared Food

A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants

Role of Pancreatic Triglyceride Content in Beta-cell Function

Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes

Liver Micro Flow - MRI

Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 Diabetes

Pharmacokinetics of Leptin Administration During Fasting

A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food

Bioequivalency Study of 450 mg Lithium Carbonate Under Fasting Conditions

The Fasting II Study

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting

Bioequivalence Study on Vitamin C in Healthy Adults

Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets 40 mg

Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects

Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

Effects of Hourly Stair-Climbing Exercise Snacks on Metabolic and Vascular Health in Adults With Prediabetes

To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants

A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults

Nutrition and Physical Activity Counseling for Nontraditional College Students

Relacorilant Food Effect Study in Healthy Subjects